List view / Grid view
In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which new candidate medications are discovered.
At the beginning of March, US President Donald Trump pressed the pharmaceutical industry to “accelerate the development” of vaccines and therapies to contain the outbreak of the coronavirus pandemic. This article explores what is currently known about COVID-19 and potential treatments that are in the pipeline.
The future of drug discovery lies in an automated world where the workflows for biological assays, chemical synthesis and data analysis are connected by flexible, mobile and modular hardware, integrated with software solutions that will interface with scientists for increased efficiency and productivity (the realisation of Industry 4.0). This article…
Scripps Research has announced it will screen over 14,000 compounds to see if any present significant activity against COVID-19, for use in a therapeutic.
A statement from scientists has highlighted that improving the understanding of COVID-19 infections in children will help researchers to develop better treatments.
New in silico screening software has the capability to screen billions of compounds, with the hope of improving drug design and limiting side effects.
Researchers have developed a new screening technique by inactivating the molecular structure of the human muscarinic receptor, allowing them to test potential drugs.
Drug Target Review explores five of the latest research developments in the field of spinal cord injury (SCI) repair.
A novel antibody has been shown to stimulate microglia to degrade amyloid plaques in a murine model of Alzheimer’s disease.
A collapsible basket technology has been developed to significantly accelerate the analysis process when scientists are developing new medicines.
A novel therapy, tested ex vivo, has been successful at correcting the dysfunctional body mechanism in Postural Orthostatic Tachycardia Syndrome (POTS).
A new microfluidic technology has been developed by researchers, which utilises magnetic ferrobots to automate chemical analyses and assays.
A collaborative team has developed a compound called WM382, which targets two crucial enzymes in the malaria parasite, effectively killing it.
The first drug designed using artificial intelligence (AI) has moved into its Phase I trial. Professor Andrew Hopkins of Exscientia explains how an algorithm was used to achieve this milestone.
Rodent models of stroke and hydrocephalus treated with ZT-1a had reduced brain swelling, according to scientists.
A computational programme has been created by researchers to aid in the design of proteins for therapeutics, to predict interactions.
